ICAR Develops India's First Indigenous African Swine Fever Vaccine to Strengthen Biosecurity

India has achieved a major breakthrough in veterinary biotechnology with the development of its first indigenous African Swine Fever (ASF) vaccine by the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD). The vaccine is expected to protect pig populations, reduce economic losses for farmers and enhance the country's livestock biosecurity while supporting the vision of Atmanirbhar Bharat.

India Develops Indigenous African Swine Fever Vaccine to Strengthen Livestock Biosecurity

A Landmark Achievement in Veterinary Biotechnology

India has taken a significant step towards strengthening animal health and livestock protection by developing its first indigenous vaccine against African Swine Fever (ASF). The breakthrough has been achieved by the Indian Council of Agricultural Research–National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal, marking an important milestone in the country's veterinary biotechnology sector.

The vaccine was formally dedicated to the nation during the ICAR Foundation Day celebrations by Union Minister for Agriculture and Farmers Welfare Shivraj Singh Chouhan, in the presence of Union Minister Rajiv Ranjan Singh. The development reflects India's growing scientific capabilities in addressing infectious animal diseases through homegrown research and innovation.

Understanding African Swine Fever

African Swine Fever is a highly contagious viral disease that affects domestic and wild pigs. Although the disease does not infect humans, it causes severe illness and extremely high mortality among pigs, resulting in major economic losses for farmers and the livestock industry.

There is currently no effective treatment available for ASF, making prevention through vaccination and biosecurity measures the most effective approach to disease control.

Since the disease was first reported in India in 2020, several states have experienced repeated outbreaks, leading to widespread pig deaths and disruptions in the pig farming sector.

How the Indigenous Vaccine Was Developed

The newly developed vaccine has been created using the widely available MA-104 cell line, making production significantly more affordable and scalable compared to proprietary manufacturing platforms used internationally.

By relying on an accessible production technology, India can manufacture the vaccine domestically at large scale without depending heavily on imported technologies or foreign intellectual property.

This achievement aligns with the government's broader objective of promoting self-reliance in biotechnology and vaccine manufacturing under the Atmanirbhar Bharat initiative.

Extensive Laboratory Testing Ensures Safety

Before being introduced for field use, the indigenous ASF vaccine underwent comprehensive scientific evaluation.

Researchers carried out multiple laboratory studies covering:

• Sterility testing

• Purity assessment

• Safety evaluation

• Genetic stability analysis

• Immunogenicity testing

• Protective efficacy studies

• Virulence reversion assessment

Following successful laboratory validation, the vaccine was tested under field conditions in collaboration with the Department of Animal Husbandry & Dairying, ensuring that it performs effectively under practical farming conditions.

These rigorous evaluations demonstrate the vaccine's potential to provide reliable protection against African Swine Fever.

Major Relief for India's Pig Farming Sector

The development of the indigenous vaccine comes at a crucial time for India's pig farming industry.

African Swine Fever outbreaks have caused extensive financial losses across several states, particularly in the North-Eastern region, where pig farming represents an important source of income for rural households.

States including Assam and Mizoram have suffered significant economic damage following repeated outbreaks over the past few years.

The availability of an effective domestic vaccine is expected to reduce pig mortality substantially, helping farmers safeguard their livestock while improving overall productivity and income stability.

Vaccination Guidelines for Farmers

The vaccine has been recommended for pigs aged more than eight weeks.

According to the recommended vaccination schedule:

• A 1 mL intramuscular injection should be administered initially.

• A booster dose should be given 14 days later to strengthen immunity.

The vaccination programme aims to build long-lasting protection while reducing the spread of infection within pig populations.

Authorities are expected to support wider vaccination campaigns in high-risk regions to improve disease preparedness nationwide.

Strengthening India's Livestock Biosecurity

The indigenous ASF vaccine represents more than just a scientific achievement—it significantly enhances India's overall livestock biosecurity framework.

Preventing large-scale disease outbreaks helps:

• Protect animal health.

• Improve food security.

• Strengthen rural livelihoods.

• Reduce emergency disease-control costs.

• Improve confidence within the livestock sector.

Stronger disease preparedness also supports India's long-term agricultural sustainability and reduces dependence on imported veterinary healthcare solutions.

Supporting the Vision of Atmanirbhar Bharat

The vaccine aligns closely with India's vision of becoming self-reliant in critical technologies. By developing indigenous vaccine technology, India demonstrates its growing capability to design, test and manufacture advanced veterinary products within the country.

Domestic production also reduces supply chain risks while ensuring rapid vaccine availability during future disease outbreaks.

The achievement highlights the expanding role of Indian research institutions in delivering practical solutions for national agricultural and animal health challenges.

Global Opportunities for India's Biotechnology Sector

The successful development of an indigenous ASF vaccine positions India among a select group of countries capable of producing vaccines against African Swine Fever.

This milestone could create new opportunities for India's biotechnology and veterinary pharmaceutical industries.

With affordable manufacturing capabilities, India may eventually emerge as a global supplier of cost-effective veterinary vaccines, particularly for countries facing similar disease challenges.

Such developments could strengthen India's presence in the international animal healthcare market while boosting biotechnology exports.

Future Outlook for Pig Farming

The introduction of the indigenous vaccine is expected to improve confidence among pig farmers and encourage greater investment in the sector.

As vaccination coverage expands, the industry could experience:

• Lower mortality rates.

• Improved livestock productivity.

• Better disease management.

• Increased farmer incomes.

• Enhanced food production.

Combined with improved surveillance and biosecurity measures, the vaccine may significantly reduce the long-term impact of African Swine Fever across India.

Conclusion

India's first indigenous African Swine Fever vaccine marks a major advancement in veterinary biotechnology and livestock disease management. Developed by ICAR-NIHSAD, the vaccine offers a scalable, affordable and scientifically validated solution to one of the most damaging diseases affecting pig farming. By reducing livestock losses, strengthening biosecurity and supporting self-reliance in vaccine production, this innovation reinforces India's commitment to sustainable agriculture, rural livelihoods and scientific excellence while opening new opportunities in the global veterinary healthcare sector.